Results 151 to 160 of about 239,525 (205)

National immunisation recommendations: why country-specific evidence and context matter. [PDF]

Lancet Reg Health Eur
Schaefer R, Harder T, Sandmann F, Wichmann O.   +3 more
europepmc   +1 more source

Current Understanding of Meningitis Pathogens, Immunity Gap, and Future Prevention Strategies in Sri Lanka: A Narrative Review. [PDF]

Int J Microbiol
Heshani T, Sandaru D, Madhushara S, Ejazi SA, Deepachandi B.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Meningococcal Vaccines

Infectious Disease Clinics of North America, 2001
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein, M, Fischer, J W, Tappero   +2 more
openaire   +2 more sources

Meningococcal carriage, meningococcal disease and vaccination

Journal of Infection, 1988
Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%)
M K, Hassan-King, R A, Wall, B M, Greenwood   +2 more
openaire   +2 more sources

Bioanalysis of Meningococcal Vaccines

Bioanalysis, 2010
Meningococcal meningitis is feared because of the rapid onset of severe disease from mild symptoms and, therefore, is an important target for vaccine research. Five serogroups, defined by the structures of their capsular polysaccharides, are responsible for the vast majority of disease.
Neil, Ravenscroft, Jun X, Wheeler, Christopher, Jones   +2 more
openaire   +2 more sources